Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies

Background: Around 30% Parkinson's disease (PD) patients develop impulse control disorders (ICDs) to D2/3 dopamine agonists and, to a lesser extent, levodopa. We aim to investigate striatal dopaminergic function in PD patients with and without ICD.Methods: PubMed, Science Direct, EBSCO, and ISI...

Full description

Bibliographic Details
Main Authors: Alice Martini, Denise Dal Lago, Nicola M. J. Edelstyn, Matteo Salgarello, Fabio Lugoboni, Stefano Tamburin
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2018.01018/full
_version_ 1811213090019082240
author Alice Martini
Denise Dal Lago
Nicola M. J. Edelstyn
Matteo Salgarello
Fabio Lugoboni
Stefano Tamburin
author_facet Alice Martini
Denise Dal Lago
Nicola M. J. Edelstyn
Matteo Salgarello
Fabio Lugoboni
Stefano Tamburin
author_sort Alice Martini
collection DOAJ
description Background: Around 30% Parkinson's disease (PD) patients develop impulse control disorders (ICDs) to D2/3 dopamine agonists and, to a lesser extent, levodopa. We aim to investigate striatal dopaminergic function in PD patients with and without ICD.Methods: PubMed, Science Direct, EBSCO, and ISI Web of Science databases were searched (from inception to March 7, 2018) to identify PET or SPECT studies reporting striatal dopaminergic function in PD patients with ICD (ICD+) compared to those without ICD (ICD–). Studies which included drug naïve patients, explored non-pharmacological procedures (e.g., deep brain stimulation), and those using brain blood perfusion or non-dopaminergic markers were excluded. Standardized mean difference (SDM) was used and random-effect models were applied. Separate meta-analyses were performed for dopamine transporter level, dopamine release, and dopamine receptors availability in the putamen, caudate, dorsal, and ventral striatum.Results: A total of 238 studies were title and abstract screened, of which 19 full-texts were assessed. Nine studies (ICD+: N = 117; ICD–: N = 175 patients) were included in the analysis. ICD+ showed a significant reduction of dopamine transporter binding in the putamen (SDM = −0.46; 95% CI: −0.80, −0.11; Z = 2.61; p = 0.009), caudate (SDM = −0.38; 95% CI: −0.73, −0.04; Z = 2.18; p = 0.03) and dorsal striatum (SDM = −0.45; 95% CI: −0.77, −0.13; Z = 2.76; p = 0.006), and increased dopamine release to reward-related stimuli/gambling tasks in the ventral striatum (SDM = −1.04; 95% CI: −1.73, −0.35; Z = 2.95; p = 0.003). Dopamine receptors availability did not differ between groups. Heterogeneity was low for dopamine transporter in the dorsal striatum (I2 = 0%), putamen (I2 = 0%) and caudate (I2 = 0%), and pre-synaptic dopamine release in the dorsal (I2 = 0%) and ventral striatum (I2 = 0%); heterogeneity was high for dopamine transporter levels in the ventral striatum (I2 = 80%), and for dopamine receptors availability in the ventral (I2 = 89%) and dorsal (I2 = 86%) striatum, putamen (I2 = 93%), and caudate (I2 = 71%).Conclusions: ICD+ patients show lower dopaminergic transporter levels in the dorsal striatum and increased dopamine release in the ventral striatum when engaged in reward-related stimuli/gambling tasks. This dopaminergic imbalance might represent a biological substrate for ICD in PD. Adequately powered longitudinal studies with drug naïve patients are needed to understand whether these changes may represent biomarkers of premorbid vulnerability to ICD.
first_indexed 2024-04-12T05:40:12Z
format Article
id doaj.art-9f41652ecd8b4d8fa6d5502d6cd3d0fb
institution Directory Open Access Journal
issn 1664-2295
language English
last_indexed 2024-04-12T05:40:12Z
publishDate 2018-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj.art-9f41652ecd8b4d8fa6d5502d6cd3d0fb2022-12-22T03:45:40ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-12-01910.3389/fneur.2018.01018416028Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT StudiesAlice Martini0Denise Dal Lago1Nicola M. J. Edelstyn2Matteo Salgarello3Fabio Lugoboni4Stefano Tamburin5School of Psychology, Keele University, Newcastle-under-Lyme, United KingdomSchool of Psychology, Keele University, Newcastle-under-Lyme, United KingdomSchool of Psychology, Keele University, Newcastle-under-Lyme, United KingdomDepartment of Nuclear Medicine, Ospedale Sacro Cuore Don Calabria, Verona, ItalyAddiction Unit, Department of Internal Medicine, University Hospital of Verona, Verona, ItalyDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, ItalyBackground: Around 30% Parkinson's disease (PD) patients develop impulse control disorders (ICDs) to D2/3 dopamine agonists and, to a lesser extent, levodopa. We aim to investigate striatal dopaminergic function in PD patients with and without ICD.Methods: PubMed, Science Direct, EBSCO, and ISI Web of Science databases were searched (from inception to March 7, 2018) to identify PET or SPECT studies reporting striatal dopaminergic function in PD patients with ICD (ICD+) compared to those without ICD (ICD–). Studies which included drug naïve patients, explored non-pharmacological procedures (e.g., deep brain stimulation), and those using brain blood perfusion or non-dopaminergic markers were excluded. Standardized mean difference (SDM) was used and random-effect models were applied. Separate meta-analyses were performed for dopamine transporter level, dopamine release, and dopamine receptors availability in the putamen, caudate, dorsal, and ventral striatum.Results: A total of 238 studies were title and abstract screened, of which 19 full-texts were assessed. Nine studies (ICD+: N = 117; ICD–: N = 175 patients) were included in the analysis. ICD+ showed a significant reduction of dopamine transporter binding in the putamen (SDM = −0.46; 95% CI: −0.80, −0.11; Z = 2.61; p = 0.009), caudate (SDM = −0.38; 95% CI: −0.73, −0.04; Z = 2.18; p = 0.03) and dorsal striatum (SDM = −0.45; 95% CI: −0.77, −0.13; Z = 2.76; p = 0.006), and increased dopamine release to reward-related stimuli/gambling tasks in the ventral striatum (SDM = −1.04; 95% CI: −1.73, −0.35; Z = 2.95; p = 0.003). Dopamine receptors availability did not differ between groups. Heterogeneity was low for dopamine transporter in the dorsal striatum (I2 = 0%), putamen (I2 = 0%) and caudate (I2 = 0%), and pre-synaptic dopamine release in the dorsal (I2 = 0%) and ventral striatum (I2 = 0%); heterogeneity was high for dopamine transporter levels in the ventral striatum (I2 = 80%), and for dopamine receptors availability in the ventral (I2 = 89%) and dorsal (I2 = 86%) striatum, putamen (I2 = 93%), and caudate (I2 = 71%).Conclusions: ICD+ patients show lower dopaminergic transporter levels in the dorsal striatum and increased dopamine release in the ventral striatum when engaged in reward-related stimuli/gambling tasks. This dopaminergic imbalance might represent a biological substrate for ICD in PD. Adequately powered longitudinal studies with drug naïve patients are needed to understand whether these changes may represent biomarkers of premorbid vulnerability to ICD.https://www.frontiersin.org/article/10.3389/fneur.2018.01018/fullParkinson's diseaseimpulse control disorderdopaminePETSPECTtransporter
spellingShingle Alice Martini
Denise Dal Lago
Nicola M. J. Edelstyn
Matteo Salgarello
Fabio Lugoboni
Stefano Tamburin
Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
Frontiers in Neurology
Parkinson's disease
impulse control disorder
dopamine
PET
SPECT
transporter
title Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
title_full Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
title_fullStr Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
title_full_unstemmed Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
title_short Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
title_sort dopaminergic neurotransmission in patients with parkinson s disease and impulse control disorders a systematic review and meta analysis of pet and spect studies
topic Parkinson's disease
impulse control disorder
dopamine
PET
SPECT
transporter
url https://www.frontiersin.org/article/10.3389/fneur.2018.01018/full
work_keys_str_mv AT alicemartini dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies
AT denisedallago dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies
AT nicolamjedelstyn dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies
AT matteosalgarello dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies
AT fabiolugoboni dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies
AT stefanotamburin dopaminergicneurotransmissioninpatientswithparkinsonsdiseaseandimpulsecontroldisordersasystematicreviewandmetaanalysisofpetandspectstudies